rolipram has been researched along with Parkinson Disease in 5 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cognitive impairment often occurs in Parkinson's disease (PD), but the mechanism of onset remains unknown." | 1.46 | Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease. ( Ishii, T; Kinoshita, KI; Muroi, Y; Unno, T, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, L | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| He, J | 1 |
| Guo, J | 1 |
| Liu, M | 1 |
| Xu, JP | 1 |
| Wang, HT | 1 |
| Zhou, ZZ | 1 |
| Kinoshita, KI | 1 |
| Muroi, Y | 1 |
| Unno, T | 1 |
| Ishii, T | 1 |
| Niccolini, F | 1 |
| Wilson, H | 1 |
| Pagano, G | 1 |
| Coello, C | 1 |
| Mehta, MA | 1 |
| Searle, GE | 1 |
| Gunn, RN | 1 |
| Rabiner, EA | 1 |
| Foltynie, T | 1 |
| Politis, M | 1 |
| Casacchia, M | 1 |
| Meco, G | 1 |
| Castellana, F | 1 |
| Bedini, L | 1 |
| Cusimano, G | 1 |
| Agnoli, A | 1 |
| Parkes, JD | 1 |
| Thompson, C | 1 |
| Brennan, L | 1 |
| Gajraj, N | 1 |
| Howcroft, B | 1 |
| Ruiz, J | 1 |
1 trial available for rolipram and Parkinson Disease
| Article | Year |
|---|---|
Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Humans; Lisuride; Middle Aged; Parkinson Disease; Pyrroli | 1983 |
4 other studies available for rolipram and Parkinson Disease
| Article | Year |
|---|---|
Discovery of arylbenzylamines as PDE4 inhibitors with potential neuroprotective effect.
Topics: Animals; Benzylamines; Cell Survival; Cyclic Nucleotide Phosphodiesterases, Type 4; Dose-Response Re | 2019 |
Rolipram improves facilitation of contextual fear extinction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cyclic AMP; Cyclic AMP Resp | 2017 |
Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain Mapping; Carbon Radioisotopes; Cognition | 2017 |
Rolipram in Parkinson's disease.
Topics: Antiparkinson Agents; Drug Therapy, Combination; Ergot Alkaloids; Humans; Levodopa; Parkinson Diseas | 1984 |